The Global Animal Gastroesophageal Reflux Disease Market was valued at USD 3.1 billion in 2024 and is estimated to grow at a CAGR of 7.5% to reach USD 6.3 billion by 2034, driven by the increasing prevalence of GERD among both companion and livestock animals, as well as advancements in veterinary diagnostics and treatments. Factors such as aging populations, obesity, and gastrointestinal infections contribute to the development of GERD in animals, leading to a higher demand for effective treatment options. The market is characterized by the availability of various diagnostic tools and therapeutic interventions, including antacids, H2 antagonists, and proton pump inhibitors, which are widely used in veterinary medicine to manage GERD symptoms. These medications help reduce stomach acid and are commonly prescribed due to their proven safety and efficacy profiles in animals.
In addition, advancements in veterinary diagnostics, such as endoscopic imaging, advanced blood panels, and ultrasound technologies, are making it easier for veterinarians to detect GERD earlier and with greater precision. This has led to an uptick in early intervention strategies, which can significantly improve outcomes and reduce long-term complications. The increasing awareness among pet owners about the impact of digestive disorders on overall pet health is also accelerating demand for both over-the-counter and prescription solutions.
The treatment segment in the animal gastroesophageal reflux disease market generated USD 1.7 billion in 2024. Medications such as antacids, H2 antagonists, and proton pump inhibitors have shown consistent effectiveness in reducing stomach acid in animals, which is crucial for controlling GERD symptoms. These medications are widely available in both human and veterinary formulations and have been used in veterinary medicine for years due to their safety and minimal side effects.
The companion animals segment held the largest share of 71.7% in 2024. Obesity in pets is on the rise, leading to nutritional deficits in many companion animals. Dietary issues often lead to the development of acid reflux, increasing the need for GERD treatment options. Certain dog breeds, such as pugs, bulldogs, and boxers, are particularly susceptible to GERD due to their unique anatomical features.
United States Animal Gastroesophageal Reflux Disease Market was valued at USD 1.2 billion in 2024, owing to the increasing number of pet ownership and the growing demand for veterinary services. There is a rising awareness among pet owners and livestock breeders regarding the importance of gastrointestinal health and its impact on overall animal well-being. Government initiatives focusing on disease prevention and animal welfare further support market growth.
Key players in the Global Animal Gastroesophageal Reflux Disease Market include Boehringer Ingelheim, Zoetis, Merck, Elanco, Hill's Pet Nutrition, IDEXX Laboratories, Kerry Group, Vetcare, Vetoquinol, and Virbac. These companies are actively involved in developing and offering a range of diagnostic and therapeutic solutions to address GERD in animals. Their efforts aim to improve the quality of life for affected animals and meet the growing demand for effective treatments in the veterinary sector. To strengthen their market position, companies in the animal GERD market are adopting various strategies. They are focusing on research and development to introduce innovative diagnostic tools and treatment options. Collaborations with veterinary clinics and research institutions are being pursued to enhance product offerings and expand market reach.
This product will be delivered within 2-4 business days.
In addition, advancements in veterinary diagnostics, such as endoscopic imaging, advanced blood panels, and ultrasound technologies, are making it easier for veterinarians to detect GERD earlier and with greater precision. This has led to an uptick in early intervention strategies, which can significantly improve outcomes and reduce long-term complications. The increasing awareness among pet owners about the impact of digestive disorders on overall pet health is also accelerating demand for both over-the-counter and prescription solutions.
The treatment segment in the animal gastroesophageal reflux disease market generated USD 1.7 billion in 2024. Medications such as antacids, H2 antagonists, and proton pump inhibitors have shown consistent effectiveness in reducing stomach acid in animals, which is crucial for controlling GERD symptoms. These medications are widely available in both human and veterinary formulations and have been used in veterinary medicine for years due to their safety and minimal side effects.
The companion animals segment held the largest share of 71.7% in 2024. Obesity in pets is on the rise, leading to nutritional deficits in many companion animals. Dietary issues often lead to the development of acid reflux, increasing the need for GERD treatment options. Certain dog breeds, such as pugs, bulldogs, and boxers, are particularly susceptible to GERD due to their unique anatomical features.
United States Animal Gastroesophageal Reflux Disease Market was valued at USD 1.2 billion in 2024, owing to the increasing number of pet ownership and the growing demand for veterinary services. There is a rising awareness among pet owners and livestock breeders regarding the importance of gastrointestinal health and its impact on overall animal well-being. Government initiatives focusing on disease prevention and animal welfare further support market growth.
Key players in the Global Animal Gastroesophageal Reflux Disease Market include Boehringer Ingelheim, Zoetis, Merck, Elanco, Hill's Pet Nutrition, IDEXX Laboratories, Kerry Group, Vetcare, Vetoquinol, and Virbac. These companies are actively involved in developing and offering a range of diagnostic and therapeutic solutions to address GERD in animals. Their efforts aim to improve the quality of life for affected animals and meet the growing demand for effective treatments in the veterinary sector. To strengthen their market position, companies in the animal GERD market are adopting various strategies. They are focusing on research and development to introduce innovative diagnostic tools and treatment options. Collaborations with veterinary clinics and research institutions are being pursued to enhance product offerings and expand market reach.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Animal Type, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)
Chapter 8 Company Profiles
Companies Mentioned
The companies featured in this Animal Gastroesophageal Reflux Disease market report include:- Boehringer Ingelheim
- Daiichi Sankyo
- Elanco Animal Health
- Hill's Pet Nutrition
- IDEXX Laboratories
- Kerry Group
- Merck
- Vetcare
- Vetoquinol
- Vibrac
- Zoetis
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 132 |
| Published | May 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 3.1 Billion |
| Forecasted Market Value ( USD | $ 6.3 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
